The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Atossa Therapeutics Inc shares valued at $9,887 were purchased by QUAY STEVEN C on May 21 ’25. At $0.88 per share, QUAY STEVEN C acquired 11,239 shares. The insider’s holdings grew to 13,898 shares worth approximately $12091.26 following the completion of this transaction.
Also, Remmel H. Lawrence purchased 10,000 shares, netting a total of over 7,000 in proceeds. Following the buying of shares at $0.70 each, the insider now holds 10,257 shares.
As published in their initiating research note from Maxim Group on January 26, 2018, Atossa Therapeutics Inc [ATOS] has been a Buy and the price target has been revised to $2.
Analyzing ATOS Stock Performance
On last trading session,, Atossa Therapeutics Inc [NASDAQ: ATOS] plunged -5.68% to $0.87. The stock’s lowest price that day was $0.87, but it reached a high of $0.94 in the same session. During the last five days, there has been a drop of approximately -1.62%. Over the course of the year, Atossa Therapeutics Inc shares have dropped approximately -40.68%.
Support And Resistance Levels for Atossa Therapeutics Inc (ATOS)
RSI (Relative Strength Index) is 50.86 on the 14-day chart, showing neutral technical sentiment.
Is Atossa Therapeutics Inc subject to short interest?
Stocks of Atossa Therapeutics Inc saw a sharp steep in short interest on 2025-07-15 dropping by -3.33 million shares to 4.09 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 7.42 million shares. A decline of -81.5% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.68 of the overall float, the days-to-cover ratio (short ratio) decline to 2.68.
Which companies own the most shares of Atossa Therapeutics Inc (ATOS)?
In terms of Atossa Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 5 in the next 12 months, up nearly 443.48% from the previous closing price of $0.92. Analysts anticipate Atossa Therapeutics Inc stock to reach 5 by 2025, with the lowest price target being 5. In spite of this, 2 analysts ranked Atossa Therapeutics Inc stock as Buy at the end of 2025.
